| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911155 | Lung Cancer | 2014 | 5 Pages |
Abstract
Dinaciclib, administered IV, was well tolerated at the 50Â mg/m2 dose, but does not have activity as monotherapy in previously treated NSCLC. Evaluation of dinaciclib in combination with other agents for other indications including breast cancer and multiple myeloma is in progress.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Joe J. Stephenson, John Nemunaitis, Anil A. Joy, Julie C. Martin, Ying-Ming Jou, Da Zhang, Paul Statkevich, Siu-Long Yao, Yali Zhu, Honghong Zhou, Karen Small, Rajat Bannerji, Martin J. Edelman,